SIGNALING BY VASOPRESSIN--ARTERIAL SMOOTH MUSCLE CELLS
加压素发出的信号——动脉平滑肌细胞
基本信息
- 批准号:6184234
- 负责人:
- 金额:$ 21.68万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1999
- 资助国家:美国
- 起止时间:1999-04-01 至 2003-03-31
- 项目状态:已结题
- 来源:
- 关键词:arginine vasopressin calcium channel calcium flux calcium indicator cell proliferation electrophysiology enzyme activity enzyme inhibitors hormone receptor hormone regulation /control mechanism immunoprecipitation laboratory rat membrane potentials phospholipase D protein kinase C protein tyrosine kinase receptor binding tissue /cell culture vascular smooth muscle vasomotion voltage gated channel
项目摘要
[Arginine8]-vasopressin (AVP) is a peptide hormone which is released from the posterior pituitary gland in response to a decrease in blood pressure or an increase in plasma osmolality. AVP is both a potent vasoconstrictor and a mitogen for vascular smooth muscle. These effects of AVP are important not only for physiological regulation of blood flow and pressure, but may also play a role in diseases, such as hypertension and atherosclerosis, which involve alterations in vascular smooth muscle contractility and proliferation, respectively. The long term objectives of this project are to understand the molecular mechanisms involved in these responses of arterial smooth muscle to AVP. Both contraction and proliferation of arterial smooth muscle cells involve an increase in cytosolic Ca2+ concentration ([Ca2+]i). In A7r5 rat aortic smooth muscle cells, AVP binds to a single class of vasopressin receptors of the V1a subtype. However, AVP has two distinct effects on [Ca2+]i in A7r5 cells: low concentrations of AVP (10-500 pM) stimulate oscillations in [Ca2+]i (Ca2+ spikes); higher concentrations (0.5-100 nM) inhibit Ca2+ spiking, but elicit a biphasic elevation of [Ca2+]i resulting from release of intracellular Ca2+ stores and increased Ca2+ influx across the plasma membrane. These two effects involve different mechanisms. AVP-stimulated Ca2+ spiking results from action potentials that depend on Ca2+ entry through L-type voltage-sensitive Ca2+ channels. The release of intracellular Ca2+ by higher concentrations of AVP is attributed to inositol trisphosphate produced as a result of activation of phospholipase C. The proposed research project will examine the signal transduction mechanisms involved in AVP-stimulated Ca2+ spiking. Preliminary studies suggest that activation of phospholipase D (PLD) is required for stimulation of Ca2+ spiking by AVP. [Ca2+]i measurements with fura-2 or indo-1 and electrophysiological methods will be used to examine the effects of AVP on whole cell membrane currents and membrane potential to test the hypothesis that AVP increases Ca2+ spiking activity by inhibiting delayed rectifier K+ currents, resulting in membrane depolarization and activation of voltage-sensitive Ca2+ channels. The involvement of PLD and the non-receptor tyrosine kinase, PYK2, in K+ channel inhibition will also be investigated using immunoprecipitation techniques. AVP-stimulated PYK2 phosphorylation and Ca2+ spiking are prevented by protein kinase C (PKC) inhibitors. Additional experiments will examine the role of specific PKC isoforms in the AVP signaling pathway and their relationship to PLD activation. Finally, the effects of AVP and other hormones on [Ca2+]i and membrane currents will be examined in freshly isolated smooth muscle cells from rat mesenteric arteries.
[精氨酸8]-加压素(AVP)是一种在血压降低或血浆渗透压升高时由脑下垂体释放的多肽激素。AVP既是一种有效的血管收缩药,又是一种血管平滑肌有丝分裂原。AVP的这些作用不仅对血流和血压的生理调节很重要,而且可能在高血压和动脉粥样硬化等疾病中发挥作用,这些疾病分别涉及血管平滑肌收缩和增殖的变化。本项目的长期目标是了解动脉平滑肌对AVP的这些反应的分子机制。动脉平滑肌细胞的收缩和增殖都涉及细胞内钙离子浓度([Ca2+]i)的升高。在A7r5大鼠主动脉平滑肌细胞中,AVP与V1a亚型的单一类型的加压素受体结合。然而,AVP对A7r5细胞的[Ca~(2+)]_i有两种不同的作用:低浓度(10~500 pm)AVP刺激[Ca~(2+)]i振荡(Ca~(2+)峰);高浓度(0.5~100 nM)抑制Ca~(2+)峰,但通过释放细胞内的Ca~(2+)和增加跨质膜的Ca~(2+)内流而引起细胞内[Ca~(2+)]i的双相升高。这两种效应涉及不同的机制。AVP刺激的Ca~(2+)放电是由动作电位引起的,动作电位依赖于钙离子通过L型电压敏感钙通道内流。较高浓度的AVP引起的细胞内钙离子释放归因于磷脂酶C激活产生的三磷酸肌醇。该研究计划将探讨AVP刺激细胞内钙离子尖峰的信号转导机制。初步研究表明,激活磷脂酶D(PLD)是AVP刺激Ca~(2+)峰所必需的。用Fura-2或Indo-1测定[Ca~(2+)]i和电生理方法,观察AVP对全细胞膜电流和膜电位的影响,以验证AVP通过抑制延迟整流钾电流,从而增加膜去极化和激活电压敏感的钙通道,从而增加钙离子尖峰活性的假说。PLD和非受体酪氨酸激酶PYK2在K+通道抑制中的作用也将用免疫沉淀技术进行研究。蛋白激酶C(PKC)抑制剂可阻止AVP刺激的PYK2磷酸化和钙离子尖峰。其他实验将研究特定的PKC亚型在AVP信号通路中的作用及其与PLD激活的关系。最后,我们将研究AVP和其他激素对新鲜分离的大鼠肠系膜动脉平滑肌细胞[Ca~(2+)]i和膜电流的影响。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
KENNETH L BYRON其他文献
KENNETH L BYRON的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('KENNETH L BYRON', 18)}}的其他基金
KCNQ Channels in Airway Smooth Muscle Physiology and Disease
KCNQ 气道平滑肌生理学和疾病中的通道
- 批准号:
9210531 - 财政年份:2016
- 资助金额:
$ 21.68万 - 项目类别:
KCNQ Channels and Vasoconstrictor Signal Transduction
KCNQ 通道和血管收缩信号转导
- 批准号:
7758181 - 财政年份:2009
- 资助金额:
$ 21.68万 - 项目类别:
KCNQ Channels and Vasoconstrictor Signal Transduction
KCNQ 通道和血管收缩信号转导
- 批准号:
8024529 - 财政年份:2009
- 资助金额:
$ 21.68万 - 项目类别:
KCNQ Channels and Vasoconstrictor Signal Transduction
KCNQ 通道和血管收缩信号转导
- 批准号:
8403740 - 财政年份:2009
- 资助金额:
$ 21.68万 - 项目类别:
KCNQ Channels and Vasoconstrictor Signal Transduction
KCNQ 通道和血管收缩信号转导
- 批准号:
7582000 - 财政年份:2009
- 资助金额:
$ 21.68万 - 项目类别:
KCNQ Channels and Vasoconstrictor Signal Transduction
KCNQ 通道和血管收缩信号转导
- 批准号:
8206590 - 财政年份:2009
- 资助金额:
$ 21.68万 - 项目类别:
Calcium entry and vascular smooth muscle excitation
钙进入和血管平滑肌兴奋
- 批准号:
6609587 - 财政年份:2003
- 资助金额:
$ 21.68万 - 项目类别:
Calcium entry and vascular smooth muscle excitation
钙进入和血管平滑肌兴奋
- 批准号:
7058719 - 财政年份:2003
- 资助金额:
$ 21.68万 - 项目类别:
Calcium entry and vascular smooth muscle excitation
钙进入和血管平滑肌兴奋
- 批准号:
6891569 - 财政年份:2003
- 资助金额:
$ 21.68万 - 项目类别:
Calcium entry and vascular smooth muscle excitation
钙进入和血管平滑肌兴奋
- 批准号:
6749575 - 财政年份:2003
- 资助金额:
$ 21.68万 - 项目类别:
相似海外基金
L-type Calcium Channel SNP rs1006737: characterizing the genetic risks in MUD (Methamphetamine Use Disorder)
L 型钙通道 SNP rs1006737:表征 MUD(甲基苯丙胺使用障碍)的遗传风险
- 批准号:
10668210 - 财政年份:2023
- 资助金额:
$ 21.68万 - 项目类别:
Development of a Novel Calcium Channel Therapeutic for the Treatment of Asthma
开发治疗哮喘的新型钙通道疗法
- 批准号:
10603554 - 财政年份:2023
- 资助金额:
$ 21.68万 - 项目类别:
Development of a Novel Calcium Channel Therapeutic for Opioid Use Disorder
开发一种治疗阿片类药物使用障碍的新型钙通道疗法
- 批准号:
10684558 - 财政年份:2023
- 资助金额:
$ 21.68万 - 项目类别:
Development of a Novel Medication for Alcohol Use Disorder with an Active IND Dual Inhibitor of T-Type Calcium Channel and Soluble Epoxide Hydrolase
使用 T 型钙通道和可溶性环氧化物水解酶的活性 IND 双重抑制剂开发治疗酒精使用障碍的新型药物
- 批准号:
10815882 - 财政年份:2023
- 资助金额:
$ 21.68万 - 项目类别:
Novel Tools to Probe Trafficking and Function of Calcium Channel Signaling Complexes in Heart
探测心脏钙通道信号复合物的运输和功能的新工具
- 批准号:
10628914 - 财政年份:2023
- 资助金额:
$ 21.68万 - 项目类别:
Mechanisms of L-type Calcium Channel Regulation in Heart Health and Disease
L 型钙通道在心脏健康和疾病中的调节机制
- 批准号:
10734121 - 财政年份:2023
- 资助金额:
$ 21.68万 - 项目类别:
Structure-Function of Calcium Channel Complexes in Cardiac Physiology and Disease
钙通道复合物在心脏生理和疾病中的结构-功能
- 批准号:
10628911 - 财政年份:2023
- 资助金额:
$ 21.68万 - 项目类别:
Research Initiation Award: Defining the role of DJ-1 in regulating L-type voltage-dependent calcium channel expression in neuronal plasticity
研究启动奖:定义 DJ-1 在调节神经元可塑性中 L 型电压依赖性钙通道表达中的作用
- 批准号:
2200474 - 财政年份:2022
- 资助金额:
$ 21.68万 - 项目类别:
Standard Grant
Design and Preclinical Development of First-in-Class Selective T-type Calcium Channel Blockers for Chronic Pain
用于治疗慢性疼痛的一流选择性 T 型钙通道阻滞剂的设计和临床前开发
- 批准号:
452107 - 财政年份:2021
- 资助金额:
$ 21.68万 - 项目类别:
Operating Grants
Preventing the Calcium Channel Blocker – Lower Extremity Edema – Loop Diuretic Prescribing Cascade in Older Adults
预防钙通道阻滞剂 – 下肢水肿 – 老年人袢利尿剂处方级联
- 批准号:
10399417 - 财政年份:2021
- 资助金额:
$ 21.68万 - 项目类别:














{{item.name}}会员




